ALMKT:EPA
Mauna Kea Technologies SA
€ 0,092
0,00%
(0,00) 1D
13 nov, 17:35:01 GMT+1 · EUR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor ALMKT genereren…
Openen
€ 0,09
Hoog
€ 0,10
Laag
€ 0,09
Beursw.
18,14 mln.
Gem. vol.
541,14K
Volume
75,16K
Koers/winst-verhouding
0,79
52 wk hoog
€ 0,23
52 wk laag
€ 0,07
WPA
€ 0,12
Uitstaande aandelen
195,26 mln.
Aantal medewerkers
56
Openen
€ 0,09
Hoog
€ 0,10
Laag
€ 0,09
Beursw.
18,14 mln.
Gem. vol.
541,14K
Volume
75,16K
Koers/winst-verhouding
0,79
52 wk hoog
€ 0,23
52 wk laag
€ 0,07
WPA
€ 0,12
Uitstaande aandelen
195,26 mln.
Aantal medewerkers
56
Nieuwsartikelen
Van webbronnen en nieuwspartners
Het Financieele Dagblad
·
1 dag geleden
Pan-Europese Stoxx 600 toont veerkracht, terwijl de Amerikaanse S&P 500 hapert
Yahoo! Finance Canada
·
6 minuten geleden
CABA,TRIN,RPC,FFIN,GO,NXRT,AVBC,CULP,ALT,BLCO,VSNT,FRST,ENTX,BLIN,GRNT,SSP,GAIA,NRGV,AFCG,APCX,THRY,KLTR | Stock Prices | Quote Comparison - Yahoo Finance
The Motley Fool
·
23 minuten geleden
The S&P 500 Has Gone 18 Months Without a 10% Drop. Here's How the Next Year Has Gone After Streaks This Long.
Foreign Policy Journal
·
59 minuten geleden
AST SpaceMobile (NASDAQ: ASTS) Carries A $10.4 Billion Valuation While Its Biggest New Contract Is Worth Just 1% Of That
Profiel
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Over Mauna Kea Technologies SA
CEOSacha Loiseau
Medewerkers56
Opgericht2000
Hoofdkantoor-
SectorHealth Care
Industrie-
Websitemaunakeatech.com